Sensitivity of tumor cells to the cytostatic action of natural killer cells and their ability to release prostaglandins of type E

1990 ◽  
Vol 110 (3) ◽  
pp. 1265-1268
Author(s):  
G. E. Klyuchareva ◽  
V. A. Matveeva ◽  
�. N. Uvarova
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Killer Cells ◽  
Cytostatic Action

Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells

2021 ◽  
Vol 160 ◽  
pp. 103261
Author(s):  
Mélanie Gauthier ◽  
Caroline Laroye ◽  
Danièle Bensoussan ◽  
Cédric Boura ◽  
Véronique Decot
Keyword(s):  
Monoclonal Antibodies ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Killer Cells

Autologous Activated and Expanded Natural Killer Cells Destroy Multiple Myeloma Clonogenic Tumor Cells through NKG2D and Its Ligands

2015 ◽  
Vol 15 ◽  
pp. e245-e246
Author(s):  
A. Leivas ◽  
R.M. Risueño ◽  
A. Pérez-Martínez ◽  
D. Campana ◽  
J.J. Lahuerta ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Killer Cells ◽  
Clonogenic Tumor Cells

MHC Class I–Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells

2005 ◽  
Vol 11 (20) ◽  
pp. 7516-7522 ◽  
Author(s):  
Claire Germain ◽  
Christel Larbouret ◽  
Valérie Cesson ◽  
Alena Donda ◽  
Werner Held ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Mhc Class I ◽  
Class I ◽  
Specific Lysis ◽  
Killer Cells ◽  
Antitumor Antibodies

scholarly journals Next-Generation Immunotherapies to Improve Anticancer Immunity

2021 ◽  
Vol 11 ◽  
Author(s):  
Yaoyao Shi ◽  
Katarzyna Tomczak ◽  
June Li ◽  
Joshua K. Ochieng ◽  
Younghee Lee ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Checkpoint Inhibitors ◽  
Cytotoxic T Cells ◽  
Cell Subset ◽  
Cytotoxic T Cell ◽  
Killer Cells

Checkpoint inhibitors are widely used immunotherapies for advanced cancer. Nonetheless, checkpoint inhibitors have a relatively low response rate, work in a limited range of cancers, and have some unignorable side effects. Checkpoint inhibitors aim to reinvigorate exhausted or suppressed T cells in the tumor microenvironment (TME). However, the TME contains various other immune cell subsets that interact to determine the fate of cytotoxic T cells. Activation of cytotoxic T cells is initiated by antigen cross-presentation of dendritic cells. Dendritic cells could also release chemokines and cytokines to recruit and foster T cells. B cells, another type of antigen-presenting cell, also foster T cells and can produce tumor-specific antibodies. Neutrophils, a granulocyte cell subset in the TME, impede the proliferation and activation of T cells. The TME also consists of cytotoxic innate natural killer cells, which kill tumor cells efficiently. Natural killer cells can eradicate major histocompatibility complex I-negative tumor cells, which escape cytotoxic T cell–mediated destruction. A thorough understanding of the immune mechanism of the TME, as reviewed here, will lead to further development of more powerful therapeutic strategies. We have also reviewed the clinical outcomes of patients treated with drugs targeting these immune cells to identify strategies for improvement and possible immunotherapy combinations.

Sign in / Sign up

Export Citation Format

Share Document